ALVOTECH
Broadening
access to biologic medicines that save
with no clinically meaningful differences in terms of safety and effectiveness from the reference product . Biosimilar drugs have a pivotal role to play in public health , as they offer additional treatment options that are typically more affordable than their branded counterparts . This is positive news for key therapeutic areas such as autoimmune diseases and cancer , which already have approved biosimilars on the market . Little wonder , then , that the global biosimilar market was valued at US $ 30bn in 2020 , and that it is expected to grow to approximately US $ 80bn over the next six years .
It ’ s one thing for Alvotech to aim to improve patient lives through broadened access to biosimilars , but how exactly can the company achieve this ? “ By making sound , strategic decisions ,” explains Helmerich .
One such decision includes Alvotech ’ s commercial strategy . Early in its life , Alvotech was debating if it should seek a global partner or go with ‘ local champions ’.
“ Ultimately , we chose a local approach ,” says Helmerich . “ Since that decision was made , we have partnered with top firms who are leaders in their markets . Being able to rely on the scale and expertise of our partners allows us to focus on what we do best - development and manufacturing .”
Another important decision is Alvotech ’ s differentiated portfolio . “ Each market is
36 February 2022